DOI QR코드

DOI QR Code

Induction of Apoptosis by IGFBP3 Overexpression in Hepatocellular Carcinoma Cells

  • Han, Jian-Jun (Department of Cancer Intervention Treatment Center, Shandong Cancer Hospital and Institute) ;
  • Xue, De-Wen (Department of Cancer Intervention Treatment Center, Shandong Cancer Hospital and Institute) ;
  • Han, Qiu-Rong (Department of Obstetrics and Gynecology, Heze Municipal Hospital) ;
  • Liang, Xiao-Hong (Department of Immunology Shandong University School of Medicine) ;
  • Xie, Li (Department of Basic Research Center, Shandong Cancer Hospital and Institute) ;
  • Li, Sheng (Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute) ;
  • Wu, Hui-Yong (Department of Cancer Intervention Treatment Center, Shandong Cancer Hospital and Institute) ;
  • Song, Bao (Department of Basic Research Center, Shandong Cancer Hospital and Institute)
  • Published : 2015.01.06

Abstract

Background: The insulin-like growth factor (IGF) system comprises a group of proteins that play key roles in regulating cell growth, differentiation, and apoptosis in a variety of cellular systems. The aim of this study was to investigate the role of insulin-like growth factor binding protein 3 (IGFBP3) in hepatocellular carcinoma. Materials and Methods: Expression of IGF2, IGFBP3, and PTEN was analyzed by qRT-PCR. Lentivirus vectors were used to overexpress IGFBP3 in hepatocellular carcinoma cell (HCC) lines. The effect of IGFBP3 on proliferation was investigated by MTT and colony formation assays. Results: Expression of IGF2, IGFBP3, and PTEN in several HCC cell lines was lower than in normal cell lines. After 5-aza-2'-deoxycytidine/trichostatin A treatment, significant demethylation of the promoter region of IGFBP3 was observed in HCC cells. Overexpression of IGFBP3 induced apoptosis and reduced colony formation in HUH7 cells. Conclusions: Expression of IGF2, IGFBP3, and PTEN in several HCC cell lines was lower than in normal cell lines. After 5-aza-2'-deoxycytidine/trichostatin A treatment, significant demethylation of the promoter region of IGFBP3 was observed in HCC cells. Overexpression of IGFBP3 induced apoptosis and reduced colony formation in HUH7 cells.

Keywords

Hepatocellular carcinoma;IGF signaling pathway;IGFBP3;proliferation

References

  1. Ailin A, Valiollah D, Dabidi R, et al (2013). Pretreatment effects of regular aerobic training on the IGF system and hepatotoxicity induced by doxorubicin in rats. Asian Pac J Cancer Prev, 14, 7427-31. https://doi.org/10.7314/APJCP.2013.14.12.7427
  2. Albrecht S, Schweinitz D, Waha A, et al (1994). Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res, 54, 5041-4.
  3. Buendia MA (2002). Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol, 39, 530-5. https://doi.org/10.1002/mpo.10180
  4. Rainier S, Dobry Cj and Feinberg AP (1995). Loss of imprinting in hepatoblastoma. Cancer Res, 55, 1836-8.
  5. Breuhahn K, Longerich T and Schirmacher P (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 25, 3787-800. https://doi.org/10.1038/sj.onc.1209556
  6. Chang YS, Wang L, Suh YA, et al (2004). Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene, 23, 6569-80. https://doi.org/10.1038/sj.onc.1207882
  7. Foulstone E, Prince S, Zaccheo O, et al (2005). Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol, 205, 145-53. https://doi.org/10.1002/path.1712
  8. Grimberg A and Cohen P (2000). Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol, 183, 1-9. https://doi.org/10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
  9. Hanafusa T, Yumoto Y, Nouso K, et al (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett, 176, 149-58. https://doi.org/10.1016/S0304-3835(01)00736-4
  10. Ibanez de Caceres I, Dulaimi E, Hoffman AM, et al (2006). Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res, 66, 5021-8. https://doi.org/10.1158/0008-5472.CAN-05-3365
  11. Kaneda A and Feinberg AP (2005). Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res, 65, 11236-40. https://doi.org/10.1158/0008-5472.CAN-05-2959
  12. Kraus JA, Albrecht S, Wiestler OD, von Schweinitz D, Pietsch T (1996). Loss of heterozygosity on chromosome 1 in human hepatoblastoma. Int J Cancer, 67, 467-71. https://doi.org/10.1002/(SICI)1097-0215(19960807)67:4<467::AID-IJC1>3.0.CO;2-Q
  13. Ma DZ, Xu Z, Liang YL, et al (2005). Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol, 11, 4472-7. https://doi.org/10.3748/wjg.v11.i29.4472
  14. Maehama T, Dixon JE (1998). The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem, 273, 13375-8. https://doi.org/10.1074/jbc.273.22.13375
  15. Mannhardt B, Weinzimer SA, Wagner M, et al (2000). Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol, 20, 6483-95. https://doi.org/10.1128/MCB.20.17.6483-6495.2000
  16. Natsuizaka M, Kinugasa H, Kagawa S, et al (2014). IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res, 4, 29-41.
  17. Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T (1996). Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res, 56, 3320-3.
  18. Rehem RN and El-Shikh WM (2011). Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology, 58, 949-54.
  19. Shin KH, Kim JM, Rho KS, et al (2002). Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol, 21, 997-1001.
  20. Steenman M, Westerveld A and Mannens M (2000). Genetics of beckwith-wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer, 28, 1-13. https://doi.org/10.1002/(SICI)1098-2264(200005)28:1<1::AID-GCC1>3.0.CO;2-#
  21. Tang SH, Yang DH, Huang W, et al (2006). Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res, 12, 4171-7. https://doi.org/10.1158/1078-0432.CCR-05-2261
  22. Tomii K, Tsukuda K, Toyooka S, et al (2007). Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer, 120, 566-73. https://doi.org/10.1002/ijc.22341
  23. Voz ML, Agten NS, VandeVen WJ, Kas K (2000). PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res, 60, 106-13.
  24. Weber RG, Pietsch T, von Schweinitz D and Lichter P (2000). Characterization of genomic alterations in hepatoblastomas: a role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol, 157, 571-8. https://doi.org/10.1016/S0002-9440(10)64567-1
  25. Ye QM, Xin X, Yi WL, et al (2013). Prostate cancer risk in relation to a single nucleotide polymorphism in the insulinlike growth factor-binding protein-3 (IGFBP3) Gene: a meta-analysis. Asian Pac J Cancer Res, 13, 6299-303

Cited by

  1. Long-term hypoxia exposure enhanced IGFBP-3 protein synthesis and secretion resulting in cell apoptosis in H9c2 myocardial cells vol.33, pp.4, 2015, https://doi.org/10.3109/08977194.2015.1077824
  2. Microarray gene expression analysis in ovine ductus arteriosus during fetal development and birth transition vol.80, pp.4, 2016, https://doi.org/10.1038/pr.2016.123
  3. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-017-3941-x